NATIONAL GLOBAL RESOLUTE PROGRAM.
revascularisation (7.7% vs 6.5%, p=0.32), and
succumbed 4 years later to generalized meta-
Farooq V, Vranckx P, Mauri L, Cutlip DE, Belardi J,
definite/probable stent thrombosis (1.4% vs
static disease. No other primary paraganglio-
Silber S, Widimsky P, Leon M, Windecker S, Mere-
0.9%, p=0.28). 13-month adjusted angio-
ma was found; however, paraganglion cells in
dith I, Negoita M, van Leeuwen F, Neumann FJ,
graphic outcomes were comparable between
the eye have never been described.
Yeung AC, Garcia-Garcia HM, Serruys PW.
overlapping and non-overlapping DES.
Keywords: Choroidal tumor, Metastatic dis-
Abstract
Conclusions: Overlapping newer generation
ease, Paraganglioma.
Background: Overlapping first generation
DES are safe and effective, with comparable
sirolimus- and paclitaxel-eluting stents are as-
angiographic and clinical outcomes-including
sociated with persistent inflammation, fibrin
repeat revascularisation-to non-overlapping
Gepubliceerd in J Fr Ophtalmol. 2013 Jan 7.
deposition and delayed endothelialisation in
DES.
INTRAVITREAL INJECTION OF ANTI-VEGF AND
preclinical models, and adverse angiographic
DIAGNOSIS OF PRIMARY INTRAOCULAR CEN-
and clinical outcomes-including death and
TRAL NERVOUS SYSTEM LYMPHOMA.
myocardial infarction (MI)-in clinical studies.
Gepubliceerd in Case Rep Ophthalmol. 2013 Jan;4(1):17-22.
Gambrelle J, Missotten G, Delhoum S, Desjardins L.
Objectives: To establish as to whether there
CHOROIDAL PARAGANGLIOMA WITH METAS-
Abstract
are any safety concerns with newer genera-
TASES TO THE FELLOW EYE.
We report a case of primary intraocular central
tion drug-eluting stents (DES).
Ginderdeuren RV, Missotten GS, van den Oord J.
nervous system (CNS) lymphoma in a patient
Design: Propensity score adjustment of
Abstract
previously treated with intravitreal anti-vascu-
baseline anatomical and clinical characteris-
Purpose: To report a case of a paraganglioma
lar endothelial growth factor (VEGF) injections
tics were used to compare clinical outcomes
in the right eye with metastatic disease in the
for age-related macular degeneration (AMD).
(Kaplan-Meier estimates) between patients
fellow eye 3 years later.
An 88-year-old woman, with past medical his-
implanted with overlapping DES (Resolute
Methods: A 70-year-old man presented with
tory significant for bilateral age-related macu-
zotarolimus-eluting stent (R-ZES) or R-ZES/
a painful amblyopic right eye; rubeosis iridis
lar degeneration (AMD) treated with intra-
other DES) against no overlapping DES. Ad-
and a large choroidal tumor were found. The
vitreal ranibizumab injections for 1year, was
ditionally, angiographic outcomes for over-
tumor was treated by enucleation. Pathology
referred to our department for bilateral vitritis
lapping R-ZES and everolimus-eluting stents
diagnosed the tumor as a paraganglioma.
diagnosed 10days after the last anti-VEGF in-
were evaluated in the randomised RESOLUTE
Screening for other tumors or metastatic dis-
jection. A complete uveitis work-up including
All-Comers Trial.
ease was negative at that moment. After 3
aqueous humour analysis, brain MRI and vitre-
Setting: Patient level data from five con-
years, a paraganglioma skin metastasis was
ous biopsy enabled us to confirm the diagnosis
trolled studies of the RESOLUTE Global
detected, and screening revealed metastatic
of primary intraocular CNS lymphoma. To the
Clinical Program evaluating the R-ZES were
disease in the liver. Another 6 months later he
best of our knowledge, this is the first report
pooled. Enrolment criteria were generally un-
was referred for tumors in the left eye, which
of the diagnosis of primary intraocular CNS
restrictive.
were treated by radiotherapy. He succumbed
lymphoma in a patient treated with anti-VEGF
Patients: 5130 patients.
6 months later.
for AMD. The differential diagnosis of vitritis
Main Outcome Measures: 2-year clinical out-
Results: Histopathology of the right eye
in elderly patients is relatively broad. Endoph-
comes and 13-month angiographic outcomes.
revealed the typical image of a paragan-
thalmitis and uveitis have been described af-
Results: 644 of 5130 patients (12.6%) in the
glioma, with expression of synaptophysin,
ter anti-VEGF injections. In such a situation,
RESOLUTE Global Clinical Program underwent
neuron-specific enolase and chromogranin.
there is actually a risk of missing the diagnosis
overlapping DES implantation. Implantation of
S-100 staining was positive in the susten-
of intraocular lymphoma in the mistaken belief
overlapping DES was associated with an in-
tacular cells; staining for HMB-45, SME, EMA
that the observed vitritis may be a reaction
creased frequency of MI and more complex/
and pan-keratin was negative. Microscopy of
to administered anti-VEGFs. If no direct time-
calcified lesion types at baseline. Adjusted
the tumors in the skin and liver 3 years later
relationship with the anti-VEGF injections can
in-hospital, 30-day and 2-year clinical out-
showed a dedifferentiated tumor with the
be found, a classic vitritis work-up should be
comes indicated comparable cardiac death
same immunological characteristics, but with
performed. Our observation suggests that ra-
(2-year overlap vs non-overlap: 3.0% vs 2.1%,
higher Ki67 expression and more mitoses.
nibizumab, at the dosage used for AMD, does
p=0.36), major adverse cardiac events (13.3%
Conclusions: This report documents a very
not impede the spread of CNS lymphoma in the
vs 10.7%, p=0.19), target-vessel MI (3.9% vs
rare choroidal paraganglioma which pre-
eye nor interfere with cytological diagnosis.
3.4%, p=0.40), clinically driven target vessel
sented clinically as a melanoma. The patient
JESSALINEA 37